Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04533737
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:44.798464+00:00
Published At
2024-01-09T00:00:00+00:00
Record Updated At
2025-03-14
Results Posted At
2024-01-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Plaque Psoriasis", "Psoriasis Vulgaris", "Psoriasis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-14"
protocolSection.identificationModule.nctId
"NCT04533737"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-01-09"

Study condition terms

  • Plaque Psoriasis (protocolSection.conditionsModule.conditions)
  • Psoriasis Vulgaris (protocolSection.conditionsModule.conditions)
  • Psoriasis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.